MARAVAI LIFESCIENCES HOLDINGS, INC.
MRVI · XNASCIK 1823239fmd_1HBDYSJVEMG6SKE7TJNF1ER4G2Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 28 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 143 | 284 | 799 | 883 | 289 | 259 | 186 |
| Cost of revenue | 67 | 80 | 141 | 169 | 149 | 151 | 152 |
| Gross profit | 76 | 204 | 659 | 714 | 140 | 108 | 34 |
| Research and development | 4 | 9 | 15 | 18 | 17 | 19 | 17 |
| Selling, general and administrative | 48 | 94 | 100 | 129 | 151 | 162 | 145 |
| Operating income | 24 | 120 | 555 | 574 | (32) | (236) | (215) |
| Interest expense | 30 | 31 | 30 | 20 | 46 | 48 | 27 |
| Interest and investment income | – | 0 | 0 | 2 | 28 | 27 | 11 |
| Other non-operating income (expense) | 0 | 0 | 0 | (0) | (1) | (2) | (4) |
| Income before taxes | (6) | 82 | 531 | 551 | 618 | (261) | (235) |
| Income tax expense | (1) | 3 | 62 | 61 | 756 | (2) | (4) |
| Net income from continuing operations | (5) | 79 | 469 | 491 | (138) | (260) | (231) |
| Net income | (4) | 89 | 182 | 220 | (119) | (145) | (131) |
| Net income to common shareholders | (8) | 77 | 182 | 220 | (119) | (145) | (131) |